Imperial College London
Alternate

ProfessorElaineHolmes

Faculty of Medicine, Department of Metabolism, Digestion and Reproduction

Professor of Chemical Biology
 
 
 
//

Contact

 

+44 (0)20 7594 3220elaine.holmes

 
 
//

Location

 

661Sir Alexander Fleming BuildingSouth Kensington Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Boulange:2019:10.1039/c8mo00190a,
author = {Boulange, CL and Rood, IM and Posma, JM and Lindon, JC and Holmes, E and Wetzels, JFM and Deegens, JKJ and Kaluarachchi, MR},
doi = {10.1039/c8mo00190a},
journal = {Molecular Omics},
pages = {39--49},
title = {NMR and MS urinary metabolic phenotyping in kidney diseases is fit-for-purpose in the presence of a protease inhibitor},
url = {http://dx.doi.org/10.1039/c8mo00190a},
volume = {15},
year = {2019}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Nephrotic syndrome with idiopathic membranous nephropathy as a major contributor, is characterized by proteinuria, hypoalbuminemia and oedema. Diagnosis is based on renal biopsy and the condition is treated using immunosuppressive drugs; however nephrotic syndrome treatment efficacy varies among patients. Multi-omic urine analyses can discover new markers of nephrotic syndrome that can be used to develop personalized treatments. For proteomics, a protease inhibitor (PI) is sometimes added at sample collection to conserve proteins but its impact on urine metabolic phenotyping needs to be evaluated. Urine from controls (n = 4) and idiopathic membranous nephropathy (iMN) patients (n = 6) were collected with and without PI addition and analysed using 1H NMR spectroscopy and UPLC-MS. PI-related data features were observed in the 1H NMR spectra but their removal followed by a median fold change normalisation, eliminated the PI contribution. PI-related metabolites in UPLC-MS data had limited effect on metabolic patterns specific to iMN. When using an appropriate data processing pipeline, PI-containing urine samples are appropriate for 1H NMR and MS metabolic profiling of patients with nephrotic syndrome.
AU  - Boulange,CL
AU  - Rood,IM
AU  - Posma,JM
AU  - Lindon,JC
AU  - Holmes,E
AU  - Wetzels,JFM
AU  - Deegens,JKJ
AU  - Kaluarachchi,MR
DO  - 10.1039/c8mo00190a
EP  - 49
PY  - 2019///
SN  - 2515-4184
SP  - 39
TI  - NMR and MS urinary metabolic phenotyping in kidney diseases is fit-for-purpose in the presence of a protease inhibitor
T2  - Molecular Omics
UR  - http://dx.doi.org/10.1039/c8mo00190a
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000459574900002&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - http://hdl.handle.net/10044/1/71111
VL  - 15
ER  -
Download